Table 3.
regimen | author | year | response/ Number of patients, response rate |
---|---|---|---|
Conventional Platinum-based |
Goff [28] |
1996 |
1/6, 17% |
Sugiyama [29] |
2000 |
3/27, 11% |
|
Ho [30] |
2004 |
4/15, 27% |
|
Takano [9] |
2006 |
5/30, 17% |
|
Taxane-Platinum |
Enomoto [31] |
2003 |
2/9, 22% |
Ho [30] |
2004 |
9/16, 56% |
|
Utsunomiya [32] |
2006 |
8/15, 53% |
|
Takano [9] |
2006 |
9/28, 32% |
|
Irinotecan-cisplatin | Takano [9] | 2006 | 3/10, 30% |